
- NSCLC (Issue 11)
- Volume 4
- Issue 2
Erlotinib Plus Bevacizumab in EGFR-Mutant NSCLC
Howard L. “Jack” West, MD, thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the combination of erlotinib plus bevacizumab (Avastin) as a frontline treatment for patients with unresectable advanced, metastatic, or recurrent <em>EGFR</em>-mutant non-small cell lung cancer (NSCLC).
Howard L. “Jack” West, MD, thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the combination of erlotinib plus bevacizumab (Avastin) as a frontline treatment for patients with unresectable advanced, metastatic, or recurrentEGFR-mutant non-small cell lung cancer (NSCLC).
While not yet available for use in the United States, the European Medicines Agency approved the combination in June 2016 and West says he regularly uses it.
Articles in this issue
about 9 years ago
Clinical Trials Exploring Bevacizumab in NSCLCabout 9 years ago
Expert Explores Treatments for Biomarker-Negative Lung Cancerabout 9 years ago
Erlotinib/Bevacizumab Combo Warrants Consideration for EGFR+ NSCLCabout 9 years ago
The Significance of Surgery Quality in NSCLCabout 9 years ago
Practice-Changing Translational Advances Predicted for NSCLCabout 9 years ago
Addressing the Challenges of Treating Non-Driver NSCLC



































